Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 925-932

  Pineda, J A ^a   Santos, J ^b   Rivero, A ^c   Abdel kader, L ^a   Palacios, R ^b   Camacho, A ^c   Lozano, F ^a   Macias J ^a   Mira, J A ^a   Vergara, S ^a   Del Valle, J ^a   Lopez L ^d   Rios Villegas M J ^e   Merino, D ^f   Giron J A ^g   Brun, F ^h   Terron A ^h   Munoz L ⁱ   Lopez M ^j   Pasquau, J ^j   Gutierrez Rave ^k   Del Arco, A ^l   Galvez M C ^m   more..

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^h HOSPITAL DE JEREZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k Hospital General Basico Santa Ana de Motril   (Spain)

^l HOSPITAL COSTA DEL SOL   (Spain)

^m HOSPITAL TORRECÁRDENAS   (Spain)

more..

Author keywords

Antiviral therapy; Cirrhosis; Hepatitis B; Hepatitis C; Liver disease

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BILIRUBIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUPERINFECTION; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; BILIRUBIN; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; MALE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TRANSAMINASES;

EID: 41149176579     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn045     Document Type: Article

References (39)

1. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004; 38 Suppl 2: S104-8.
2. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004; 38 Suppl 2: S49-55.
3. Roca B, Suarez I, Gonzalez J et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect 2003; 47 117-24.
4. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
5. Mira JA, Macías J, Girón-González JA et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2006; 58: 140-6.
6. Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196 670-6.
7. Casado J, Aranzábal L, Moya J et al. HAART-associated hepatotoxicity in HIV/HCV-co-infected patients with cirrhosis. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2006. Abstract 889. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38 Suppl 2: S90-7.
9. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS 2003; 17: 2603-14.
10. Wood R, Phanuphak P, Cahn P et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36: 684-92.
11. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
12. Johnson M, Grinsztein B, Rodríguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-8.
13. Pérez-Elías MJ, Gatell JM, Flores J et al. Effect of ritonavir-boosted atazanavir (ATV/R) in experienced HIV-infected patients regarding hepatitis B/C status. In: Abstracts of the Third IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005. Abstract TuPe1:1C25.
14. Pineda JA, Palacios R, Rivero A et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother 2006; 57: 1016-7.
15. Witek J, Mc Callister S, Odeshoo L et al. Safety of atazanavir (ATV) and atazanavir/ritonavir (ATV/R) in subjects co-infected with HIV and hepatitis B and/or C: 1100 subject-years of treatment exposure. In: Abstracts of the Sixteenth International AIDS Conference, Toronto, Canada, 2006. Poster WEPE0054.
16. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
17. Foucher J, Chanteloup E, Vergniol J et al. Diagnosis of cirrhosis by transient elastography (Fibroscan®): A prospective study. Gut 2006; 55: 403-8.
18. Vergara S, Macias J, Rivero A et al. The utility of transient elastometry in assessing liver fibrosis in patients with HIV/HCV coinfection. Clin Infect Dis 2007; 45: 969-74.
19. Macías J, Girón-González JA, González-Serrano M et al. Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes. Gut 2006; 55: 409-14.
20. Casado J, Aranzabal L, Moya J et al. Risk of liver toxicity in HCV/HIV coinfected patients with advanced chronic liver disease or cirrhosis receiving nevirapine, efavirenz or lopinavir/r. In: Abstracts of the Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005. Abstract TuPe1.1C39.
21. Benhamou Y, Mats V, Walczak D. Systemic overview of HAART-associated liver enzyme elevations in patients infected with HIV and co-infected with HCV. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2006. Abstract 88. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
22. Bristol-Myers Squibb. Reyataz Prescribing Information. www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_ PPI%20where%20PPI_SEQ=103 (20 September 2007, date last accessed).
23. Moltó J, Santos JR, Valle M et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-intected patients in routine clinical practice. Ther Drug Monit 2007; 29 648-51.
24. Rodríguez-Novoa S, Martín-Carbonero L, Barreiro P et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21: 41-6.
25. García-Samaniego J, Forns X. Hepatitis C virus and human immunodeficiency virus: The un-won battle. Hepatology 2007; 46 611-4.
26. Castellares C, Martin-Carbonero L, Barreiro P et al. Prevalence, etiology, and clinical presentation of HIV patients with liver cirrhosis. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 2006. Abstract 977. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
27. Barreiro P, Rodríguez-Novoa S, Labarga P et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007; 195: 973-8.
28. Peng JZ, Pulido F, Causemaker SJ et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 265-74.
29. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services. October 10, 2006; 1-113. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (1 November 2007, date last accessed).
30. Expert Committee of GESIDA and the National AIDS Plan. Recommendations of GESIDA/Spanish AIDS Plan on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2007). Enferm Infecc Microbiol Clin 2007, 25: 32-53.
31. Hermida JM, Quereda C, Moreno A et al. Efficacy and safety of atazanavir in HIV-infected patients with liver cirrhosis. In: Abstracts of the Fourth IAS Conference on HIV Pathogenesis and Treatment, Sydney, Australia, 2007. Abstract MoP1.B060 TuPe1.1C25.
32. de Ledinghen V, Douvin C, Kettanen A at al. Diagnosis of hepatic fibrosis and cirrhosis by transient, elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41 175-9.
33. Macias J, Mira JA López-Cortés LF et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antiviral Ther 2006; 11: 839-46.
34. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
35. Al-Mohri H, Murphy T, Lu Y et al. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a non-invasive marker. J Acquir Immune Defic Syndr 2007; 44: 463-9.
36. Noor MA, Flint OP, Maa JF et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 10: 1813-21.
37. Fartoux L, Poujol-Robert A, Guechot J et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1006-8.
38. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-15.
39. Merchante N, Macías J, Ramayo E et al. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2006; 13: 449-56.